Fungal organism (previously misclassified as protozoan)
Cannot be cultured on standard media
Obligate extracellular pathogen
Trophic and cyst life forms in alveoli
Transmission
Airborne transmission from colonized or infected individuals
Asymptomatic carriage common in immunocompetent hosts
Reactivation of latent infection in immunosuppressed hosts
Disease mechanisms
Alveolar filling
Organisms fill alveolar spaces with foamy exudate
Interstitial pneumonitis with mononuclear infiltrate
Surfactant dysfunction from alveolar damage
Gas exchange impairment
Diffusion defect as primary mechanism of hypoxemia
Ventilation-perfusion mismatch
Diffusing capacity for carbon monoxide markedly reduced
Progression to ARDS
Cytokine storm in severe cases
Neutrophil-mediated lung injury
Bilateral alveolar infiltrates with refractory hypoxemia
Therapeutic Considerations
Treatment strategy rationale
TMP-SMX as preferred first-line agent
Inhibits folate synthesis in Pneumocystis
Broadest evidence base and lowest cost
Oral bioavailability allows IV-to-PO transition
Corticosteroid rationale
Attenuates inflammatory response during organism kill
Reduces alveolar damage from cytokine release
Most survival benefit in first week of treatment
Class I evidence for HIV patients with PaO2 <70 mmHg
Leucovorin avoidance
Pneumocystis lacks dihydrofolate reductase capable of using exogenous folate
Leucovorin supplementation rescues Pneumocystis and reduces drug efficacy
Prophylaxis strategy
Primary prophylaxis indications
HIV: CD4 <200 cells per mm3 or prior AIDS-defining illness
Transplant: all solid organ recipients for 6-12 months post-transplant
Hematologic malignancy on intensive therapy
Prolonged corticosteroid use >=20 mg daily for >=4 weeks
Secondary prophylaxis
After completing PCP treatment: continue TMP-SMX until CD4 >200 for >=3 months on ART
TMP-SMX 1 DS tablet daily or 3 times per week
ART as prevention
ART-mediated CD4 recovery eliminates PCP risk
CD4 >200 sustained for 3 months allows prophylaxis discontinuation
Diagnostic approach considerations
Empiric treatment acceptable in high-probability cases
BAL often performed after empiric initiation
Treatment does not significantly reduce BAL sensitivity within first few days
Clinical non-response by day 7 requires re-evaluation
Bronchoscopy if not already performed
Co-infection or alternative diagnosis
Patient Discharge Instructions
copy discharge instructions
Pneumocystis pneumonia home care
Take all medications exactly as prescribed for the full 21 days
Do not stop antibiotics early even if feeling better
Take trimethoprim-sulfamethoxazole with plenty of fluids
If prescribed atovaquone, take with a fatty meal each time
Rest and avoid strenuous activity during recovery
Avoid contact with people who are sick
Warning signs to return to emergency immediately
Worsening shortness of breath or difficulty breathing at rest
Chest pain (could indicate pneumothorax)
Lips or fingertips turning blue
Fever not improving after 5-7 days of treatment
Widespread rash especially involving mouth, eyes, or genitals
May indicate Stevens-Johnson syndrome from trimethoprim-sulfamethoxazole
Inability to take medications due to vomiting
Confusion, extreme sleepiness, or difficulty waking
Fainting or near-fainting
Follow-up instructions
Mandatory follow-up within 3-5 days to reassess oxygen levels
Complete the full 21-day antibiotic course
After treatment, continue daily preventive antibiotic as prescribed
Return for repeat blood work including CD4 count as directed
HIV care follow-up if not already engaged
Prevention after recovery
Continue prophylactic antibiotics until immune system recovers
Adhere to HIV medications (ART) every day
Keep all specialist appointments
References
Guidelines and key sources
Primary guidelines
IDSA and DHHS Opportunistic Infections Guidelines 2025
Benson et al. Guidelines for Prevention and Treatment of OIs in Adults with HIV
DHHS/OARAC 2025 adult and adolescent OI guidelines
AST Infectious Diseases Community of Practice 2019
Fishman JA, Gans H — Pneumocystis jiroveci in solid organ transplantation
Clinical Transplantation 2019
DHHS 2025 pediatric OI guidelines
Kapogiannis et al. — Guidelines for Prevention and Treatment of OIs in Children with HIV
Key clinical studies
Thomas CF, Limper AH — Pneumocystis Pneumonia
New England Journal of Medicine 2004
LDH >495 U/L mortality prediction 70% sensitivity and specificity
Lemiale V et al. — PIC trial adjunctive corticosteroids in non-HIV PCP
Lancet Respiratory Medicine 2025
Double-blind RCT of corticosteroids in non-HIV severe PCP
Schmidt JJ et al. — Clinical course of PCP over 17 years
Critical Care 2018
Gaborit BJ et al. — Outcome and prognostic factors of PCP
Annals of Intensive Care 2019
Sun R et al. — Diagnostic accuracy of beta-D-glucan and LDH for non-HIV PCP
Scientific Reports 2021
Giacobbe DR et al. — PCP in ICUs multicenter study ESGCIP and EFISG
Critical Care 2023
Pirracchio R et al. — Low-dose corticosteroids for severe pulmonary infections
JAMA 2024
Jaramillo Cartagena A et al. — Laboratory diagnosis of Pneumocystis jirovecii
Journal of Clinical Microbiology 2025
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.